Figure 1
Patient-Focused Next Generation Home Blood Test for Cardiometabolic Health Now Available to Consumers
August 28, 2023 12:08 ET | CardioMetaboliQ LLC
—An alarming 93 percent of US adults have less than optimal cardiometabolic health1 and many are completely unaware of their risk— —New test provides end-to-end cardiometabolic health solution, with...
Imbria_Logo_Colour.png
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
August 16, 2023 08:00 ET | Imbria Pharmaceuticals Inc.
– IMPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023 – – Additional Phase 2 data read-outs expected in 4Q 2023, including topline from the IMPROVE-HCM...
Imbria_Logo_Colour.png
Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect
May 17, 2023 08:00 ET | Imbria Pharmaceuticals Inc.
BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
SelectHealth Brings
SelectHealth Brings Vida Health Virtual Health Solutions to Members Managing Chronic Conditions
March 14, 2023 11:00 ET | SelectHealth
Salt Lake City, Utah, March 14, 2023 (GLOBE NEWSWIRE) -- SelectHealth®, a nonprofit health plan serving more than one million members in Utah, Idaho, and Nevada, is pleased to announce a new...
New Cardiometabolic
New Cardiometabolic Health Hub Hosted by Healio
February 23, 2023 08:00 ET | Cardiometabolic Health Congress
Boca Raton, FL, Feb. 23, 2023 (GLOBE NEWSWIRE) -- The experts at Cardiometabolic Health Congress (CMHC) announced today that their media partner Healio will host the Cardiometabolic Health Hub, a...
Imbria_Logo_Colour.png
Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction
January 09, 2023 08:00 ET | Imbria Pharmaceuticals Inc.
BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
Imbria_Logo_Colour.png
Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy
December 05, 2022 08:00 ET | Imbria Pharmaceuticals Inc.
BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
Imbria_Logo_Colour.png
Imbria Pharmaceuticals to Participate in BMO’s Fall Private Company Showcase
October 10, 2022 08:00 ET | Imbria Pharmaceuticals Inc.
BOSTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
Imbria_Logo_Colour.png
Imbria Pharmaceuticals to Participate in the UBS Biotechnology Private Company Virtual Symposium
September 15, 2022 08:00 ET | Imbria Pharmaceuticals Inc.
BOSTON, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
Imbria_Logo_Colour.png
Imbria Presents Positive Clinical Data for Ninerafaxstat from IMPROVE-DiCE at the European Society of Cardiology Congress 2022
August 26, 2022 08:15 ET | Imbria Pharmaceuticals Inc.
BOSTON, Mass., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today...